 |
|
|
| |
Sustained Virologic Response 12 Weeks Post-treatment With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With Ribavirin (SAPPHIRE I and II)
Is Independent of Patient Subgroups
|
| |
| |
Reported by Jules Levin
Presented at the American College of Gastroenterology-79th Annual Scienti fi c Meeti ng, October 17-22, 2014, Philadelphia, Pennsylvania, United States
Maurizia Rossana Brunett o1, Mihály Makara2, Holger Hinrichsen3, John Hanson4, Michael Bennett 5, Eric Lawitz6, Bo Fu7, Eoin Coakley7, Guy Neff 7
1Liver Unit, University Hospital of Pisa, Pisa, Italy; 2Saint Laszlo Hospital, Budapest, Hungary; 3Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany; 4Charlott e Gastroenterology & Hepatology, PLLC, Charlott e, North Carolina, United States; 5Medical Associate Research Group, Inc., San Diego, California, United States;
6Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 7AbbVie Inc., North Chicago, Illinois, United States
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAďVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
NEJM Publications:
TURQUOISE-II ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis - Phase 3 TURQUOISE-II - (04/14/14)
SAPPHIRE-I Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin (in previously untreated patients with HCV genotype 1 infection and no cirrhosis) - (04/11/14)
SAPPHIRE-II Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin - (04/10/14) NEJM
|
| |
|
|
|
|
|
